News from imprimis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 03, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Feb 02, 2015, 16:01 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Announces Two Key Leadership Promotions

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Jan 13, 2015, 07:30 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals to Highlight its Proprietary Ophthalmic Solutions at the Hawaiian Eye 2015 and the Cataract Surgery: Telling It Like It Is! Meetings

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Jan 08, 2015, 08:00 ET
Imprimis Pharmaceuticals Logo

Imprimis Pharmaceuticals Looks to Expand its Ophthalmology Portfolio with LessDrops™

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Jan 05, 2015, 08:00 ET

Imprimis Pharmaceuticals Appoints Dr. Richard L. Lindstrom to its Board of Directors

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary...

Dec 03, 2014, 08:00 ET

Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations to Four Key Western States

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Dec 02, 2014, 08:05 ET

Imprimis Pharmaceuticals Signs Agreement to Acquire PCAB-Accredited Pharmacy in California

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary...

Nov 12, 2014, 16:00 ET

Imprimis Pharmaceuticals Reports on Third Quarter 2014 Financial Results and Provides Update on Business Developments

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Nov 06, 2014, 08:00 ET

Imprimis Pharmaceuticals to Host its Third Quarter 2014 Financial Report Conference Call and Webcast on November 12, 2014

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary...

Nov 04, 2014, 08:00 ET

Imprimis Pharmaceuticals Signs Distribution Agreement to Bring Go Dropless™ Proprietary Formulations to Ophthalmologists in Puerto Rico

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Oct 29, 2014, 08:31 ET

Imprimis Pharmaceuticals Enters into License Agreement for Patented Urology Formulation

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) today announced that it has entered into a license agreement, under which Imprimis acquired the...

Oct 24, 2014, 08:00 ET

Imprimis Pharmaceuticals Reports on Positive Clinical Findings Presented at the American Academy of Ophthalmology (AAO) Annual Meeting

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of...

Oct 16, 2014, 08:00 ET

Imprimis Pharmaceuticals' Dropless Formulations to be Presented in Multiple Sessions at the 2014 American Academy of Ophthalmology (AAO) Meeting

 Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of high...

Sep 16, 2014, 08:00 ET

Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to...

Sep 08, 2014, 08:00 ET

Imprimis Pharmaceuticals Appoints Healthcare Leader William H. Nelson to its Board of Directors

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to...

Aug 13, 2014, 16:30 ET

Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable...

Jul 24, 2014, 08:00 ET

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Featured in Two Sessions at the 2014 American-European Congress of Ophthalmic Surgery (AECOS) Summer Symposium

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and...

Jun 24, 2014, 08:00 ET

Imprimis Pharmaceuticals Go Dropless™ Video Interview Survey Reveals 95% of Leading Cataract Surgeons Surveyed Would Prefer Dropless Therapy

 Imprimis Pharmaceuticals, Inc. (Nasdaq:IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality,...

May 28, 2014, 08:00 ET

Imprimis Pharmaceuticals to Exhibit Go Dropless™ Cataract Surgery Formulations at 2014 Kiawah Eye Meeting

 Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality,...

Apr 22, 2014, 08:00 ET

Imprimis Pharmaceuticals' Go Dropless™ Cataract Surgery Formulations to be Presented in Two Sessions at the 2014 American Society of Cataract and Refractive Surgery (ASCRS) Annual Symposium & Congress

Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company focused on the development and...